Wearable Injectors and Connected Devices Conference 2019

SMi Group9 - 10 October 2019, London, UK.
SMi is proud to present the inaugural Wearable Injectors and Connected Devices Conference, taking place in London. The global wearable devices market size is expected to reach a value of $12.1 billion USD by 2021 with time dependent delivery, large volume administration with minimal injection pain and the use of connectivity to enhance user-value being key factors driving the market.

With this in mind, the conference will explore new technologies and advances of on-body devices for the administration of viscous and large molecule drug delivery, and evaluate the impact of IoT, connectivity and enhancement of user-interface, which make up core components within the wearable devices field.

Benefits of Attending

  • Listen to case studies from leading pharmaceutical companies revolutionising the medical device industry
  • Hear how on-body injectors are facilitating the administration of time-dependent, large volume and viscous drug delivery
  • Assess how connectivity is being used to improve patient adherence, health-monitoring and enhancing the user-interface
  • Explore the compatibility, pain and patient handling considerations projecting wearable devices as the future of drug delivery

Join Wearable Injectors and Connected Devices Conference 2019 in October 2019 to have the opportunity to network with Global Device Development Managers, Senior Connectivity Engineers, Leaders in Device Data Generation, Human Factors Directors and many more.

Plus two interactive pre-conference workshops

Tuesday 8th October 2019

Cross company collaboration to develop digital therapeutic solutions using connected devices

Workshop Leader: Digby Harris, Global Category Manager - Digital Therapeutics & Devices, AstraZeneca

Wearable injectors: Envisioning their evolution to address current and future unmet needs

Workshop Leader: James Blakemore, Senior Consultant, Cambridge Consultants
Workshop Leader: Sergio Marlorni, Senior Consultant, Cambridge Consultants

Who should attend?

Executives, Directors, VPs, Heads, Principals, Managers of: Drug-delivery developers, Autoinjectors, Device Engineering, Human Factor, Scientist, Product, Injectables, Packaging, Regulatory Affairs, Connectivity, Medical Device Data, Novel Product Technology, Smart device developers, Training device developers, Device-safety solution providers, Drug developers or anyone who works with Wearable Devices/ On-Body Injectors within pharmaceutical, biotech and solution providers.

To register please visit: www.wearable-injectors.co.uk/wpnwl

Early-Bird Rates

  • Book by 31st May and save £400
  • Book by 28th June and save £300
  • Book by 30th August and save £200

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

SK bioscience and GSK start Phase 3 trial of adjuv…

SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination wit...

Blood vessels produce growth factor that promotes …

Blood vessels supply tumors with nutrients and, on the other hand, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a dista...

No serious health effects linked to mRNA COVID-19 …

Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 v...

First-in-human clinical trial for a vaccine to tre…

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by resear...

New study examines 'Achilles heel' of cancer tumou…

Researchers at the University of British Columbia's faculty of medicine and BC Cancer Research Institute have uncovered a weakness in a key enzyme that solid tumour cance...

AI algorithm solves structural biology challenges

Determining the 3D shapes of biological molecules is one of the hardest problems in modern biology and medical discovery. Companies and research institutions often spend ...

A drug costing less than €2 a day helps in the tre…

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at th...

Sandoz strengthens pipeline by entering into agree…

Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). B...

Pfizer and BioNTech submit a variation to EMA with…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that they submitted a variation to the European Medicines Agency (EMA) requesting to update the Condition...

Rheumatoid arthritis treated with implanted cells …

With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically ...

One in three Americans had COVID-19 by the end of …

A new study published in the journal Nature estimates that 103 million Americans, or 31 percent of the U.S. population, had been infected with SARS-CoV-2 by the end of 20...

NIH scientists build a cellular blueprint of multi…

Chronic lesions with inflamed rims, or "smoldering" plaques, in the brains of people with multiple sclerosis (MS) have been linked to more aggressive and disabling forms ...